Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies
- 1 June 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in AIDS
- Vol. 14 (9), 1195-1201
- https://doi.org/10.1097/00002030-200006160-00017
Abstract
SCOPUS: ar.jinfo:eu-repo/semantics/publisheKeywords
This publication has 16 references indexed in Scilit:
- Saquinavir delays the emergence of zidovudine resistance in HIV-1 seropositive patients treated with combination therapyJournal of Medical Virology, 1998
- Antiretroviral treatment in 1998The Lancet, 1998
- Resistance to Human Immunodeficiency Virus Type 1 Protease InhibitorsAntimicrobial Agents and Chemotherapy, 1998
- Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor NelfinavirAntimicrobial Agents and Chemotherapy, 1998
- Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure.The Journal of Infectious Diseases, 1998
- Virological and clinical implications of resistance to HIV-1 protease inhibitorsDrug Resistance Updates, 1998
- Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patientsAIDS, 1997
- Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination TherapyScience, 1995
- Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolatesAntimicrobial Agents and Chemotherapy, 1994
- Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.Proceedings of the National Academy of Sciences, 1993